Natalie Leverone

Natalie Leverone currently serves as a Sickle Cell Therapeutic Specialist at Pfizer since June 2024. Previously, Natalie held the position of Corporate Accounts Director at Kedrion Biopharma from April 2022 to August 2024. At Biogen, from July 2021 to April 2022, Natalie was a Senior Territory Business Manager responsible for launching Aduhelm, the first new Alzheimer's drug in over 17 years. Natalie also worked at KORU Medical Systems as National Sales Director and National Account Manager from August 2019 to July 2021, and served as Corporate Account Manager for McKesson Plasma and Biologics from August 2017 to August 2019, following the acquisition of BDI Pharma, where Natalie was a Corporate Account Manager from August 2008 to August 2019. Natalie began the career in sales at Novartis Pharma between 2006 and 2008 and holds a Bachelor of Arts degree in Mass Communication/Media Studies from the University of South Florida, completed in 2005.